Thu Sep 26 14:00:00 UTC 2024: ## Acupressure Shows Promise for Chemotherapy-Induced Neuropathy: New Study
**Baltimore, MD (September 26, 2024) –** A new randomized controlled trial, currently underway, aims to evaluate the efficacy of auricular point acupressure (APA) in managing Chemotherapy-Induced Neuropathy (CIN), a debilitating side effect of cancer treatment. The study, led by researchers at Johns Hopkins University and the University of Texas Health Science Center at Houston, will assess APA’s impact on pain, numbness, tingling, and physical function.
CIN affects over 70% of cancer patients, significantly impacting their quality of life and functional ability. While current treatments often rely on medications with potential side effects, APA offers a non-invasive and non-pharmacological alternative.
This study will compare three groups: participants receiving in-person APA treatment, a sham control group receiving virtual APA instructions, and a waitlist control group receiving standard care. Researchers will analyze changes in CIN symptoms and physical function, as well as examine the effects of APA on pain sensitivity, brain connectivity, inflammation, and opioid use.
“Our pilot studies suggest that APA could be a viable alternative for managing CIN symptoms,” stated Dr. Nada Lukkahatai, lead author of the study protocol. “This new study aims to provide stronger evidence of its efficacy and unravel the underlying mechanisms behind its potential benefits.”
The study is expected to enroll 225 participants and will utilize rigorous assessments, including fMRI scans, to evaluate the impact of APA on brain function and neural pathways related to pain perception.
The findings of this study could potentially pave the way for APA to become a standard treatment option for CIN, offering a safe and effective alternative for cancer patients seeking relief from this debilitating side effect.
First Piper 